SAN FRANCISCO, CA–(Marketwired – May 26, 2016) – Managing both acquisitions and internal growth at the same time is difficult for most small companies, akin to drinking water and singing at the same time. Not so for Nobilis Health Corp. (NYSE: HLTH) (TSX: NHC), which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue. The conductor is merger-and-acquisition specialist Kolin Ozonian, who brings years of business development experience in large-cap healthcare to this small-cap enterprise. In this interview with The Life Sciences Report, Ozonian discusses his company’s newest technology and talks about how Nobilis will achieve critical mass.

The Life Sciences Report: The Q1/16 numbers for Nobilis Health Corp. were very positive. I noted from your press release that your revenue increased by $13.4 million ($13.4M) to $51.3M in Q1, which was record revenue for you. That represents a 35% increase over Q1/15. You acquired the three new centers last year, but what other factors were responsible for that growth?

Kolin Ozonian: You nailed it on the head in terms of acquiring the three new facilities in the past year. But I think it’s important to note that our acquisitions of late have been surgical hospitals. The difference between a surgical hospital and a surgical center is that surgical hospitals enable surgeons to do much more complex procedures, which can have up to a 72-hour inpatient cycle, whereas at an ambulatory surgical center, the patient goes home the same day. The physicians operating in the surgical hospitals are able to do more complex procedures to help patients, but at the same time these facilities are outside the traditional big-hospital model, where patients may be in beds for long periods of time. Our surgical hospitals are state-of-the-art and top-of-the-line, where complex surgical procedures that command a higher fee are performed.

Continue reading this interview: How Nobilis Health Will Break Out of the Healthcare Payment Mold

About Streetwise Reports –

The Life Sciences Report

Investors rely on The Life Sciences Report
to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

Nobilis Health Corp. paid Streetwise Reports to produce and distribute this interview. Kolin Ozonian had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Ozonian and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports’ terms of use and full legal disclaimer.

Forward Looking Statements:

This press release contains certain forward-looking statements within the meaning of Canadian and United States securities laws, including the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to the risk that we may face challenges managing our new Marketing Segment and may not realize anticipated benefits; our ability to successfully maintain effective internal controls over financial reporting; our ability to implement our business strategy, manage the growth in our business, and integrate acquired businesses; the risk of litigation and investigations, and liability claims for damages and other expenses not covered by insurance; the risk that payments from third-party payers, including government healthcare programs, may decrease or not increase as costs increase; adverse developments affecting the medical practices of our physician limited partners; our ability to maintain favorable relations with our physician limited partners; our ability to grow revenues by increasing case and procedure volume while maintaining profitability at the Nobilis Facilities; failure to timely or accurately bill for services; our ability to compete for physician partners, patients and strategic relationships; the risk of changes in patient volume and patient mix; the risk that laws and regulations that regulate payments for medical services made by government healthcare programs could cause our revenues to decrease; the risk that contracts are cancelled or not renewed or that we are not able to enter into additional contracts under terms that are acceptable to us; and the risk of potential decreases in our reimbursement rates. The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect us in an adverse manner. 

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. Subject to a mandatory requirements of applicable law, we disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed on March 15, 2016, as updated by other filings with the Securities and Exchange Commission. 

Jim Patrick
Email contact